Other Events ·
On September 14, 2026, Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and…
ASNDAscendis Pharma A/S
On September 14, 2026, Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration agreement with Novo Nordisk A/S, previously announced in November 2024. Under the agreement terms, all licenses granted to Novo Nordisk for these indications revert to Ascendis, and neither party has continuing financial obligations to the other. Ascendis Pharma is a biopharmaceutical company focused on developing transformative therapies for serious diseases.